Clinical Trials Logo

Neoplasia clinical trials

View clinical trials related to Neoplasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03415126 Completed - Cancer Clinical Trials

A Study of ASN007 in Patients With Advanced Solid Tumors

Start date: January 19, 2018
Phase: Phase 1
Study type: Interventional

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

NCT ID: NCT02065297 Completed - Solid Tumor Clinical Trials

Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)

Start date: July 28, 2009
Phase:
Study type: Observational

The aim of this open, controlled, multicentre biomedical research study is to identify new markers specifically associated with Horton's disease. This would make it possible to improve the diagnosis and management of this disease. Participation consists in taking one or several blood samples depending on the group patients/controls.

NCT ID: NCT01962103 Completed - Cancer Clinical Trials

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Start date: December 4, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.

NCT ID: NCT01954836 Completed - Cancer Clinical Trials

Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial

FIT
Start date: October 2013
Phase: N/A
Study type: Interventional

Hypothesis: Fasting before (48h) and one day after chemotherapy may protect normal cells from the adverse effects of chemotherapy. Design: Within a randomized controlled pilot trial 30 female patients with gynecological cancer (ovarian and breast cancer)and 4-6 scheduled chemotherapies will be randomized to fast 60-72 hours during the first half of chemotherapies or during the second half of chemotherapies and to proceed normocaloric food intake during the other cycles.Sequence of fasting and normocaloric food intake will be randomized. Assessments of adverse effects, quality of life and laboratory values take place 24 and 7 days after each chemotherapy. Statistical analyses compare summarized differences of fasted and non-fasted chemotherapy cycles.

NCT ID: NCT01523912 Completed - Neoplasia Clinical Trials

Radiofrequency Ablation for the Treatment of Gastric Dysplasia

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma. In the last few years, radiofrequency ablation (RFA) has become a recognized tool in the treatment of dysplastic Barrett's esophagus, but its use in gastric dysplasia has not yet been studied. The investigators aim to study the efficacy, safety and tolerability of RFA in the treatment of dysplastic gastric mucosa.

NCT ID: NCT00339989 Completed - Cervical Cancer Clinical Trials

Cervical Cancer Early Endpoints and Determinants

Start date: September 12, 2003
Phase:
Study type: Observational

This study, conducted by the National Cancer Institute and the University of Oklahoma, will look for changes in cervix cells and other samples that may be signs of cervical disease. Human papilloma virus, or HPV, is a common infection of the genitalia in women that usually goes away by itself. If HPV infection does not go away, it might turn into cancer of the cervix, although this is rare. This study will examine why many HPV infections go away and why a few persist and lead to cervical cancer. Women 18 years of age and older who are referred for colposcopy (examination of the vagina and cervix using an instrument with a magnifying lens) at the University of Oklahoma following Pap smear diagnosis may be eligible for this study. Women will be in one of the following diagnostic categories: - Cancer: Stage 1-2 only. - Precancer: Cervical intraepithelial neoplasia (CIN3). - HPV-infected: Positive for any of the 13 known cancer-causing HPV types, but not diagnosed with cancer or CIN3. - Normal: Negative for cancer-causing HPV and normal tissue laboratory results. Participants will undergo the following procedures: - Questionnaire: Covers demographic information (such as age, race, ethnicity, marital status, etc.), pregnancy history, menstrual and sexual history, contraceptive history, hormone medication history, medical history, smoking history, physical development, family history, and health care access. - Blood test: 2 tablespoons of blood drawn. - Colposcopy. - Procedure to collect a sample of cervical cells and fluids for HPV testing and research.